NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...
Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback